HOME > COLUMN

COLUMN

Maurer's Healthcare Insight (82)／Questions from the Floor P. Reed Maurer

December 18, 2006
Maurer's Healthcare Insight (81)

November 20, 2006
Maurer's Healthcare Insight (80)

October 23, 2006
Maurer's Healthcare Insight (79)　Back from the Saddle P. Reed Maurer

September 25, 2006
Maurer's Healthcare Insight (78) Infinite Value of a Good Boss　P. Reed Maurer

August 28, 2006
Maurer's Healthcare Insight (77)

July 24, 2006
Maurer's Healthcare Insight (76)

June 26, 2006
Maurer's Healthcare Insight (75)

May 29, 2006
Maurer's Healthcare Insight (74)

April 10, 2006
Maurer's Healthcare Insight (73)

March 13, 2006
Maurer's Healthcare Insight (71)

December 19, 2005
Maurer's Healthcare Insight (70)

November 28, 2005
Maurer's Healthcare Insight(69)

November 14, 2005
Maurer's Healthcare Insight (68)

October 17, 2005
Maurer's Healthcare Insight (67)

September 26, 2005
Maurer's Healthcare Insight (66)

August 8, 2005
Maurer's Healthcare Insight (65)

July 11, 2005
Maurer's Healthcare Insight (64)

June 13, 2005
Maurer's Healthcare Insight (63)

May 30, 2005
Maurer's Healthcare Insight (62)

April 25, 2005

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…